176 related articles for article (PubMed ID: 35861824)
1. Candidate Plasma Biomarkers to Detect Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors: A Case Control Study in the Dutch Childhood Cancer Survivor Study.
Leerink JM; Feijen EAM; Moerland PD; de Baat EC; Merkx R; van der Pal HJH; Tissing WJE; Louwerens M; van den Heuvel-Eibrink MM; Versluys AB; Asselbergs FW; Sammani A; Teske AJ; van Dalen EC; van der Heiden-van der Loo M; van Dulmen-den Broeder E; de Vries ACH; Kapusta L; Loonen J; Pinto YM; Kremer LCM; Mavinkurve-Groothuis AMC; Kok WEM
J Am Heart Assoc; 2022 Jul; 11(14):e025935. PubMed ID: 35861824
[TBL] [Abstract][Full Text] [Related]
2. Early myocardial oedema can predict subsequent cardiomyopathy in high-dose anthracycline therapy.
Muehlberg F; Kornfeld M; Zange L; Ghani S; Reichardt A; Reichardt P; Schulz-Menger J
ESC Heart Fail; 2023 Feb; 10(1):616-627. PubMed ID: 36404640
[TBL] [Abstract][Full Text] [Related]
3. Cardiac biomarkers and association with subsequent cardiomyopathy and mortality among adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort.
Dixon SB; Howell CR; Lu L; Plana JC; Joshi VM; Luepker RV; Durand JB; Ky B; Lenihan DJ; Jefferies JL; Green DM; Ehrhardt MJ; Mulrooney DA; Folse TE; Partin RE; Santucci AK; Howell RM; Srivastava DK; Hudson MM; Robison LL; Ness KK; Armstrong GT
Cancer; 2021 Feb; 127(3):458-466. PubMed ID: 33108003
[TBL] [Abstract][Full Text] [Related]
4. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.
Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B
J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034
[TBL] [Abstract][Full Text] [Related]
5. Cardiac biomarkers indicate a need for sensitive cardiac imaging among long-term childhood cancer survivors exposed to anthracyclines.
Ylänen K; Poutanen T; Savukoski T; Eerola A; Vettenranta K
Acta Paediatr; 2015 Mar; 104(3):313-9. PubMed ID: 25393922
[TBL] [Abstract][Full Text] [Related]
6. Elevations in High-Sensitive Cardiac Troponin T and N-Terminal Prohormone Brain Natriuretic Peptide Levels in the Serum Can Predict the Development of Anthracycline-Induced Cardiomyopathy.
Bisoc A; Ciurescu D; Rădoi M; Tântu MM; Rogozea L; Sweidan AJ; Bota DA
Am J Ther; 2020; 27(2):e142-e150. PubMed ID: 30648987
[TBL] [Abstract][Full Text] [Related]
7. Myocardial dysfunction in long-term breast cancer survivors treated at ages 40-50 years.
Jacobse JN; Steggink LC; Sonke GS; Schaapveld M; Hummel YM; Steenbruggen TG; Lefrandt JD; Nuver J; Crijns APG; Aleman BMP; van der Meer P; Gietema JA; van Leeuwen FE
Eur J Heart Fail; 2020 Feb; 22(2):338-346. PubMed ID: 31696625
[TBL] [Abstract][Full Text] [Related]
8. Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathy.
Muehlberg F; Funk S; Zange L; von Knobelsdorff-Brenkenhoff F; Blaszczyk E; Schulz A; Ghani S; Reichardt A; Reichardt P; Schulz-Menger J
ESC Heart Fail; 2018 Aug; 5(4):620-629. PubMed ID: 29673122
[TBL] [Abstract][Full Text] [Related]
9. Altered Peripheral Blood Gene Expression in Childhood Cancer Survivors With Anthracycline-Induced Cardiomyopathy - A COG-ALTE03N1 Report.
Singh P; Shah DA; Jouni M; Cejas RB; Crossman DK; Magdy T; Qiu S; Wang X; Zhou L; Sharafeldin N; Hageman L; McKenna DE; Armenian SH; Balis FM; Hawkins DS; Keller FG; Hudson MM; Neglia JP; Ritchey AK; Ginsberg JP; Landier W; Bhatia R; Burridge PW; Bhatia S
J Am Heart Assoc; 2023 Oct; 12(19):e029954. PubMed ID: 37750583
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults.
Dodos F; Halbsguth T; Erdmann E; Hoppe UC
Clin Res Cardiol; 2008 May; 97(5):318-26. PubMed ID: 18193371
[TBL] [Abstract][Full Text] [Related]
11. Role of NT-proBNP in detection of myocardial damage in childhood leukemia survivors treated with and without anthracyclines.
Mladosievicova B; Urbanova D; Radvanska E; Slavkovsky P; Simkova I
J Exp Clin Cancer Res; 2012 Oct; 31(1):86. PubMed ID: 23057994
[TBL] [Abstract][Full Text] [Related]
12. Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series.
Cil T; Kaplan AM; Altintas A; Akin AM; Alan S; Isikdogan A
Clin Drug Investig; 2009; 29(2):131-7. PubMed ID: 19133708
[TBL] [Abstract][Full Text] [Related]
13. Genome-Wide Association Study Identifies
Wang X; Singh P; Zhou L; Sharafeldin N; Landier W; Hageman L; Burridge P; Yasui Y; Sapkota Y; Blanco JG; Oeffinger KC; Hudson MM; Chow EJ; Armenian SH; Neglia JP; Ritchey AK; Hawkins DS; Ginsberg JP; Robison LL; Armstrong GT; Bhatia S
J Clin Oncol; 2023 Mar; 41(9):1758-1769. PubMed ID: 36508697
[TBL] [Abstract][Full Text] [Related]
14. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines.
Mavinkurve-Groothuis AM; Groot-Loonen J; Bellersen L; Pourier MS; Feuth T; Bökkerink JP; Hoogerbrugge PM; Kapusta L
Pediatr Blood Cancer; 2009 May; 52(5):631-6. PubMed ID: 19127569
[TBL] [Abstract][Full Text] [Related]
15. Long-term cardiac effects of treatment for childhood leukemia.
Urbanova D; Urban L; Simkova I; Danova K; Mikuskova E; Mladosievicova B
Neoplasma; 2010; 57(2):179-83. PubMed ID: 20099983
[TBL] [Abstract][Full Text] [Related]
16. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
[TBL] [Abstract][Full Text] [Related]
17. Improved Cardiomyopathy Risk Prediction Using Global Longitudinal Strain and N-Terminal-Pro-B-Type Natriuretic Peptide in Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy.
Ehrhardt MJ; Liu Q; Mulrooney DA; Rhea IB; Dixon SB; Lucas JT; Sapkota Y; Shelton K; Ness KK; Srivastava DK; McDonald A; Robison LL; Hudson MM; Yasui Y; Armstrong GT
J Clin Oncol; 2024 Apr; 42(11):1265-1277. PubMed ID: 38207238
[TBL] [Abstract][Full Text] [Related]
18. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.
Blanco JG; Sun CL; Landier W; Chen L; Esparza-Duran D; Leisenring W; Mays A; Friedman DL; Ginsberg JP; Hudson MM; Neglia JP; Oeffinger KC; Ritchey AK; Villaluna D; Relling MV; Bhatia S
J Clin Oncol; 2012 May; 30(13):1415-21. PubMed ID: 22124095
[TBL] [Abstract][Full Text] [Related]
19. Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors.
Armenian SH; Gelehrter SK; Vase T; Venkatramani R; Landier W; Wilson KD; Herrera C; Reichman L; Menteer JD; Mascarenhas L; Freyer DR; Venkataraman K; Bhatia S
Clin Cancer Res; 2014 Dec; 20(24):6314-23. PubMed ID: 24947931
[TBL] [Abstract][Full Text] [Related]
20. Cardiac biomarkers for the detection of cardiotoxicity in childhood cancer-a meta-analysis.
Michel L; Mincu RI; Mrotzek SM; Korste S; Neudorf U; Rassaf T; Totzeck M
ESC Heart Fail; 2020 Apr; 7(2):423-433. PubMed ID: 32069386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
